Hagop Kantarjian, MD, professor and chair in the Department of Leukemia at the University of Texas MD Anderson Cancer Center, and Nitin Jain, MD, a professor of medicine in the Department of Leukemia at the University of Texas MD Anderson Cancer Center and renowned expert in chronic lymphocytic leukemia (CLL), discuss the latest advancements and promising therapies in CLL.
In the discussion, Dr. Jain provided an overview of novel treatments that may potentially lead to cures for subsets of CLL patients. The conversation covered therapeutic combinations, including Bruton tyrosine kinase (BTK) inhibitors with venetoclax and CD20 antibodies, as well as the future of CLL treatment, and its potential to change the prognosis for patients worldwide.
Leave feedback about this